Skip to content

Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy

Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01568346
Enrollment
9
Registered
2012-04-02
Start date
2012-02-29
Completion date
2013-03-31
Last updated
2016-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Newly diagnosed, Early stage

Brief summary

This study is being done to find out the number of surgical procedures required to achieve clear margins in women with newly diagnosed early stage breast carcinoma. The investigators are also looking at the number of additional biopsies performed before surgery, the mastectomy rate, detection of breast cancer on the opposite side (contralateral carcinoma), time form diagnosis to local therapy, and evaluation time to local recurrence.

Detailed description

This is a prospective pragmatic trial randomizing women diagnosed with early stage breast cancer to MRI versus no breast MRI. Data analyzed will include medical record information abstracted from the clinical records. Date and modality of all imaging performed, malignancy(s) identified, abnormalities identified, image guided procedures performed, surgical procedures performed and pathology results. The primary aim of this study is to assess if the use of pre-operative MRI can reduce the incidence of re-excisions required to achieve clear margins in women with newly diagnosed early stage breast carcinoma.

Interventions

OTHERMRI

Breast MRI

Sponsors

Dana-Farber Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must undergo definitive local therapy with either breast conserving therapy or mastectomy * Clinical Stage 0, I or II breast cancer based on examination and/or conventional imaging of mammogram with or without ultrasound. Tumors must be less than 5 cm in size and the patient clinically node negative * Able to undergo breast MRI

Exclusion criteria

* Not pregnant or breastfeeding * No prior breast MRI for the newly diagnosed carcinoma at the outside hospital * No prior mantle radiation * No locally advanced breast cancer * No diffuse malignant appearing microcalcifications requiring mastectomy * No known collagen vascular disease * No previous ipsilateral radiation * No participants who undergo surgery at an outside institution * No prior history of breast carcinoma

Design outcomes

Primary

MeasureTime frameDescription
Assess if pre-operative MRI reduces incidence of re-excisions required2 yearsAssess if the use of pre-operative MRI can reduce the incidence of re-excisions required to achieve clear margins in women with newly diagnosed early stage breast carcinoma

Secondary

MeasureTime frameDescription
Total Mastectomy Rates2 yearsTotal Mastectomy Rates
Number of biopsies2 yearsThe number of biopsies recommended and performed
Local-regional recurrence rates2 yearsLocal-regional recurrence rates in participants undergoing local therapy
Time from diagnosis to local therapy2 yearsThe time from diagnosis to definitive local therapy
Number of malignancies in contralateral breast2 yearsThe number of malignancies identified int he contralateral breast

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026